Clinical Documents

To edit the draft, click on the text box below.

×

Draft a comprehensive differential diagnosis for acute substernal chest pain in a 45-year-old male with hypertension and hyperlipidemia, diaphoresis, exertional onset, and normal initial ECG/troponin; include life-threatening causes first, key distinguishing features, and immediate diagnostic next steps.

Draft a detailed differential diagnosis for new-onset unilateral throbbing headache with visual aura and brief monocular vision loss in a 32-year-old female on oral contraceptives; include red-flag symptoms, stroke/TIA considerations, and recommended initial workup.

Draft an assessment and plan for stage-2 hypertension (BP 162/98) in an obese 52-year-old with suspected obstructive sleep apnea; include ASCVD risk estimate, lifestyle prescriptions, first-line pharmacotherapy with drug/dose/targets, baseline labs/monitoring, and 4–6 week follow-up.

Draft an assessment and plan for type 2 diabetes follow-up with A1c 9.2% on metformin 1,000 mg BID and eGFR 65; compare adding a GLP-1 receptor agonist vs an SGLT2 inhibitor, address weight loss goals, hypoglycemia education, vaccinations, and micro/macrovascular screening.

Draft a history and physical for a patient presenting with chest pain, including HPI using OLDCARTS, pertinent ROS, PMH/meds/allergies, FH/SH, focused cardiac/pulmonary exam, initial labs and imaging orders, prioritized differential, HEART score risk stratification, and early management.

Draft a history and physical for a new patient with progressive exertional dyspnea, orthopnea, and bilateral leg edema; include differential (heart failure, COPD, PE, anemia, renal disease), targeted exam maneuvers, and first-line diagnostics and management.

Draft a progress note for COPD follow-up two weeks after an acute exacerbation treated with prednisone and antibiotics; include symptom trajectory, CAT score (if available), inhaler technique/adherence, oxygen needs, spirometry plan, smoking cessation counseling, and return precautions.

Draft a progress note for post-operative day 2 after total knee arthroplasty; include pain control strategy, DVT prophylaxis, PT/OT milestones, wound status, bowel/urinary function, labs/vitals review, complications screening, and discharge readiness.

Draft a discharge summary for community-acquired pneumonia admission; include admission/discharge dates, presenting symptoms, radiology/labs, pathogen if identified, inpatient therapies and response, discharge medications with durations, pending tests, follow-up appointments, and return precautions.

Draft a discharge summary for myocardial infarction managed with PCI and drug-eluting stent placement; include cath findings, complications, inpatient course, discharge medications (DAPT, statin, beta-blocker, ACEi/ARB), cardiac rehab referral, and follow-up plan.

Draft discharge instructions for a patient hospitalized with acute decompensated heart failure; include daily weights, sodium and fluid restriction amounts, medication list with dosing, signs of worsening heart failure, follow-up appointments, and lab monitoring plan.

Draft discharge instructions for an asthma exacerbation; include controller and reliever regimen, steroid taper schedule, spacer technique, trigger avoidance, a written asthma action plan, return precautions, and follow-up timing.

Draft a patient handout on managing high blood pressure in plain language; explain what BP numbers mean, key lifestyle steps (DASH diet, sodium limits, alcohol moderation), home BP monitoring instructions, medication adherence tips, and when to call the doctor.

Draft a patient handout for type 2 diabetes education in plain language; cover A1c goals, the plate method, physical activity targets, self-monitoring of blood glucose, hypoglycemia signs and the 15-15 rule, foot care basics, and a vaccination checklist.

Draft a summary of the latest CDC and WHO guidelines for managing community-acquired pneumonia in adults, including empiric antibiotic choices, duration of therapy, and follow-up recommendations.

Draft a plain-language overview of the ADA and AACE guidelines for diabetes management, focusing on A1c goals, weight management, and the use of GLP-1 receptor agonists and SGLT2 inhibitors.

Draft a summary of the 2024 USPSTF breast cancer screening recommendations, including updated screening intervals, risk-based approaches, and the role of MRI for high-risk patients.

Draft a concise summary of NCCN guidelines for melanoma management, including staging, surgical margins, adjuvant therapy, and checkpoint inhibitor recommendations.

Draft treatment alternatives for community-acquired MRSA skin infections in patients allergic to sulfa drugs; include oral and IV options, dosing, and duration.

Draft treatment alternatives for patients with type 2 diabetes who are unable to tolerate GLP-1 receptor agonists due to nausea; include medication substitutions and lifestyle recommendations.

Draft a summary of options for treating refractory depression, comparing ketamine infusions, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT).

Draft treatment options for advanced prostate cancer, including hormonal therapy, radiopharmaceuticals, and novel androgen receptor pathway inhibitors.

Draft a summary of recent research on mRNA vaccine technology beyond COVID-19, including applications in oncology and autoimmune disease prevention.

Draft an easy-to-understand overview of long COVID research, summarizing major symptoms, hypothesized mechanisms, and emerging treatment approaches.

Draft a summary of current research on Alzheimer’s disease biomarkers, including amyloid and tau imaging, and discuss how they influence diagnosis and trial design.

Draft an explanation of the interaction between warfarin and antibiotics such as ciprofloxacin or TMP-SMX, including INR effects and management recommendations.

Draft a summary evaluating drug interactions for patients taking Paxlovid and common cardiovascular drugs; include mechanism and recommended dose adjustments.

Draft a summary of the common and serious side effects of semaglutide, including GI intolerance, gallbladder disease, and thyroid-related warnings.

Draft an overview of potential side effects associated with long-term corticosteroid use, including osteoporosis, glucose intolerance, and adrenal suppression.

Draft a summary of essential lab tests to order in suspected acute pancreatitis, including amylase, lipase, liver enzymes, and metabolic panels, with interpretation guidance.

Draft laboratory workup recommendations for suspected hypothyroidism, including TSH, free T4, thyroid antibodies, and when to consider secondary causes.

Draft an explanation of which labs should be monitored in patients receiving methotrexate therapy, including CBC, LFTs, renal function, and frequency of monitoring.

why choose us

Edit Geo

×

300×250 Ad Slot

Research Article: GLP-1 receptor agonists alleviate inflammatory responses and endothelial dysfunction in atherosclerosis by activating the Sema3A/NRP1 pathway

Date Published: 2026-05-12

Abstract:
This study aimed to investigate the mechanism by which GLP-1 RAs activate the Sema3A/NRP1 signaling pathway to alleviate inflammation and endothelial dysfunction in atherosclerosis (AS). Ten 8-week-old male C57BL/6J mice served as controls (CON) and received intraperitoneal injections of saline every 2 days. Forty ApoE ?/? mice were fed a 60?kcal% fat high-fat diet for 12 weeks. From weeks 13 to 24, the ApoE ?/? mice were randomly divided into 4 groups ( n =?10): AS model group (AS, saline injections), low/high-dose GLP-1 RAs group (L/H-GLP-1 RAs, 30/60??g/kg semaglutide injections) and atorvastatin group (ATO, 1.3?mg/kg atorvastatin injections as a positive control). For rescue experiments, endothelial-specific NRP1 knockout ( NRP1 EC-KO ) mice were generated. Thirty NRP1 WT mice were divided into 3 groups ( n =?10): NRP1 WT control group ( NRP1 WT CON), the NRP1 WT AS model group ( NRP1 WT AS) and the NRP1 WT AS model?+?high dose GLP-1 RAs group ( NRP1 WT +?H-GLP-1 RAs). While twenty NRP1 EC-KO mice were divided into NRP1 EC-KO AS and NRP1 EC-KO +?H-GLP-1 RAs groups ( n =?10). Mouse body weight was monitored weekly during interventions, and mice were euthanized with 120?mg/kg pentobarbital sodium at the end of experiments. HUVECs were divided into five groups ( n =?3): CON, ox-LDL, L-GLP-1 RAs, H-GLP-1 RAs, ATO. Except for controls, cells were treated with 100??g/mL ox-LDL for 24?h to establish the model. CCK-8 assays determined low/high semaglutide doses (1/2??M), while atorvastatin was applied at 10??M. Rescue experiments included CON, ox-LDL, H-GLP-1 RAs, and NRP1 inhibition?+?H-GLP-1 RAs groups, with the latter pre-treated with 0.5??M NRP1 inhibitor EG01377 for 2?h before interventions. Compared to controls, AS group mice exhibited significant weight gain from week 15 ( P <?0.001), while H-GLP-1 RAs and ATO groups showed reduced weight from week 21 ( P <?0.05). The AS group had elevated serum TC, LDL-C, IL-6, HDL-C, TNF-?, ET-1, TG levels, and percentage of plaque collagen-positive area ( P <?0.001), alongside decreased NO levels ( P <?0.001), all of which were improved by GLP-1 RAs ( P <?0.05). H&E staining revealed reduced inflammatory cell infiltration in aortic roots of semaglutide- and atorvastatin-treated mice. Aortic tissues from AS group mice showed decreased Sema3A/NRP1 expression and binding ( P <?0.05), increased p-ERK1/2/ERK1/2 and p-NF-?B p65/NF-?B p65 ratios ( P <?0.05), which were reversed by semaglutide, with higher doses showing greater effects. Immunofluorescence confirmed that Sema3A and NRP1 mainly localized in vascular endothelial cells. In ox-LDL-induced HUVECs, GLP-1 RAs improved cell viability, migration capacity, and tubule numbers ( P <?0.05), reduced IL-6 and TNF-? levels ( P <?0.05), upregulated eNOS ( P <?0.05), and downregulated VCAM-1 and ICAM-1 ( P <?0.05). Western blot and co-immunoprecipitation results aligned with in vivo trends. In vitro , EG01377 reversed GLP-1 RAs' protective effects ( P <?0.05). In vivo , GLP-1 RAs' therapeutic efficacy was significantly weakened in NRP1 EC-KO mice ( P <?0.05). GLP-1 RAs alleviate inflammation and endothelial dysfunction to reduce the atherosclerosis progression by activating the Sema3A/NRP1 pathway and inhibiting downstream ERK1/2-NF-?B signaling.

Introduction:
Atherosclerosis (AS) represents the primary pathological basis of cardiovascular diseases. It can induce life-threatening complications such as myocardial infarction, cerebral infarction and renal atrophy, and has become a global public health burden ( 1 ). Excessive activation of inflammatory response and vascular endothelial dysfunction are the core pathological processes in the development of AS ( 2 ). Endothelial dysfunction compromises the integrity of vascular barrier, promoting lipid deposition and…

Read more

300×250 Ad Slot

×
Chat & Ask Questions Career Openings Medical Doctors Check on Drug
Interactions Latest Health News
by WebHealthNetwork Get CME Credits Latest Clinical Trials Latest Research Articles Clinical Documents Update Profile

News

Chat

HCP Tools

Careers

Update Profile